drugset / Trial / NCT06352359
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841. The Phase 1 part is dose escalation with 7 dose levels of ONC-841 and the dose expansion in the last dose level. The Phase 2 part will test the combination of ONC-841 with SOC in GBM and in CRC.
Timeline
- Start
- 2024-08-23
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ONC-841 | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.